阿兹海默症治疗市场、机会、成长动力、产业趋势分析与预测，2024-2032

由于政府资金和支持的增加，阿兹海默症治疗市场规模从 2024 年到 2032 年的复合年增长率预计将达到 9.8%。

世界各国政府正投入大量资金进行研发，旨在发现阿兹海默症的有效治疗方法和潜在疗法。这种财政支持使科学家能够深入研究创新的治疗途径，包括药物开发、基因治疗和尖端诊断工具。此外，公共机构和私人实体之间加强的伙伴关係正在推动治疗方案的进步。例如，2023年1月，美国FDA加速批准Leqembi（lecanemab-irmb）。这项认可标誌着在解决阿兹海默症核心病理学方面取得的关键进展。

阿兹海默症治疗产业分为药物类别、给药途径、配销通路和地区。

由于越来越重视透过同时针对与疾病相关的多种途径来提高治疗效果，组合药物类别的市场份额预计将在 2024 年至 2032 年实现强劲的复合年增长率。这些组合药物利用不同的机制来解决阿兹海默症的各个方面，包括减少淀粉样蛋白斑块和增强认知功能。正在进行的研究正在深入研究这些多标靶药物的潜力，表明它们可能提供超越传统单一药物疗法的整体方法。

从配销通路来看，阿兹海默症治疗市场的线上药局领域预计在2024 年至2032 年期间将出现显着的复合年增长率。 。线上平台不仅提供一系列阿兹海默症治疗方法，包括尖端疗法，而且还确保增强隐私性以及订购和交付的便利性，以显着帮助患者管理自己的病情。

到 2032 年，亚太地区的阿兹海默症治疗产业将实现大幅复合年增长率。随着老年人口的增加，对有效治疗的需求也会增加。作为回应，研究人员和医疗保健专业人员正在推出量身定制的治疗方法，以满足这个不断扩大的人口的独特需求。对抗阿兹海默症的加强关注不仅可以改善治疗方案，还可以改善患者的治疗效果，以确保在其患病率不断上升的情况下更好地进行疾病管理。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 阿兹海默症的盛行率不断增加
    • 诊断技术的进步
    • 意识和诊断率不断提高
    • 优惠报销政策
  • 产业陷阱与挑战
    • 药物研发成本高
    • 临床试验失败率高
• 成长潜力分析
• 监管环境
• 管道分析
• 按疾病阶段
• 波特的分析
• PESTEL分析
• 未来市场趋势
• 差距分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 供应商矩阵分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按药物类别，2021 - 2032 年

• 主要趋势
• 胆碱酯酶抑制剂
• NMDA受体拮抗剂
• 组合药物
• 谷氨酸抑制剂
• 单胺氧化酶抑制剂
• 其他药物类别

第 6 章：市场估计与预测：按管理途径，2021 年至 2032 年

• 主要趋势
• 口服
• 可注射
• 透皮贴剂

第 7 章：市场估计与预测：按配销通路划分，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售药房
• 网路药房

第 8 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca
• Biogen
• Cipla Inc.
• Daiichi Sankyo Company, Limited
• Eisai Co., Ltd.
• Eli Lilly and Company
• H. Lundbeck A/S
• Merck and Co., Inc.
• Novartis AG
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer, Inc.
• Sanofi
• Sun Pharmaceutical Industries Ltd.

Alzheimer's Therapeutics Market size is set to record a 9.8% CAGR from 2024 to 2032 due to increased government funding and support.

Governments worldwide are channeling significant funds into R and D, aiming to discover effective treatments and potential cures for Alzheimer's disease. This financial backing empowers scientists to delve into innovative therapeutic avenues, encompassing drug development, gene therapy, and cutting-edge diagnostic tools. Furthermore, the strengthened partnerships between public institutions and private entities are propelling advancements in treatment options. For instance, in January 2023, the U.S. FDA granted accelerated approval to Leqembi (lecanemab-irmb). This endorsement signifies a pivotal advancement in addressing the core pathology of Alzheimer's disease.

The alzheimer's therapeutics industry is segmented into drug class, route of administration, distribution channel, and region.

The market share from the combination drug class segment is poised to witness a robust CAGR from 2024 to 2032 attributed to the growing emphasis on enhancing treatment efficacy by simultaneously targeting multiple pathways associated with the disease. These combination drugs leverage diverse mechanisms to tackle various facets of Alzheimer's, including reducing amyloid plaques and boosting cognitive functions. Ongoing research is delving into the potential of these multi-targeted agents, suggesting they might offer a holistic approach for outpacing traditional single-drug therapies.

By distribution channel, the online pharmacy segment of the alzheimer's therapeutics market is set to experience a notable CAGR from 2024 to 2032. This is fueled by the increasing consumer demand for convenient medication access. Online platforms are not only providing a spectrum of Alzheimer's treatments, including cutting-edge therapies but are also ensuring enhanced privacy and ease in ordering and delivery to significantly aid patients in managing their conditions.

Asia Pacific alzheimer's therapeutics industry will register a substantial CAGR through 2032. This growth is driven by an aging populace and the surging prevalence of Alzheimer's in the region. As the elderly population swells, the demand for effective treatments will also rise. In response, researchers and healthcare professionals are rolling out tailored therapeutics to meet the unique needs of this expanding demographic. The intensified focus on combating Alzheimer's is not only refining treatment options but also bolstering patient outcomes to ensure better disease management amidst its rising prevalence.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of Alzheimer's disease
    • 3.2.1.2 Technological advancements in diagnostics
    • 3.2.1.3 Growing awareness and diagnosis rates
    • 3.2.1.4 Favorable reimbursement policies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of drug development
    • 3.2.2.2 High failure rate in clinical trials
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 By stage of disease
• 3.7 Porter's analysis
• 3.8 PESTEL analysis
• 3.9 Future market trends
• 3.10 GAP analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Vendor matrix analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Cholinesterase inhibitors
• 5.3 NMDA receptor antagonist
• 5.4 Combination drugs
• 5.5 Glutamate inhibitors
• 5.6 MAO inhibitors
• 5.7 Other drug classes

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Injectable
• 6.4 Transdermal patch

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacy
• 7.3 Retail pharmacy
• 7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AbbVie Inc.
• 9.2 Amgen Inc.
• 9.3 AstraZeneca
• 9.4 Biogen
• 9.5 Cipla Inc.
• 9.6 Daiichi Sankyo Company, Limited
• 9.7 Eisai Co., Ltd.
• 9.8 Eli Lilly and Company
• 9.9 H. Lundbeck A/S
• 9.10 Merck and Co., Inc.
• 9.11 Novartis AG
• 9.12 Otsuka Pharmaceutical Co., Ltd.
• 9.13 Pfizer, Inc.
• 9.14 Sanofi
• 9.15 Sun Pharmaceutical Industries Ltd.